5612 Results

People

  1. Giralt
    Giralt
  2. Ladanyi
    Ladanyi
  3. Arcila
    Arcila
  4. Perales
    Perales
  5. Drilon
    Drilon
  6. Hyman
    Hyman
  7. Berger
    Berger
  8. Solit
    Solit
  9. Motzer
    Motzer
  10. Reis-Filho
    Reis-Filho

Groups

  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)
  7. Center for Hematologic Malignancies (914)
  8. Survivorship Research (910)
  9. Department of Pathology and Laboratory Medicine (784)
  10. Population Sciences Research Program (751)
  1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Shukla, M.; Salcedo, J. M.; Vemuri, S.; Kinoshita, J. C.; Smith, M. D.; Winer, E. S.; Abdel-Wahab, O.; Tallman, M. S.
    Blood (2019)

    Fulltext@MSK | Save
  • SIERRA clinical trial dosimetry results support low dose anti-CD45 iodine (131I) apamistamab [Iomab-B] for targeted lymphodepletion prior to adoptive cell therapy
    Meeting Abstract

    Nath, R.; Geoghegan, E. M.; Ulrickson, M. L.; Spross, J. A.; Lichtenstein, R. H.; Konerth, S.; Fisher, D. R.; Liang, Q.; Ludwig, D.; Reddy, V.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Cognitive impairment is associated with inferior survival and increased non-relapse mortality in older allogeneic hematopoietic cell transplant (alloHCT) recipients: A multicenter retrospective study
    Meeting Abstract

    Olin, R. L.; Fretham, C.; Pasquini, M. C.; Arora, M.; Bhatt, V. R.; Derman, B.; Giralt, S. A.; Huang, L. W.; Koll, T. T.; Lee, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Clinical and functional studies reveal that TP73 isoforms levels are associated with prognosis and RA-resistance in acute promyelocytic leukemia
    Meeting Abstract

    Rojas, C. A. O.; Pereira-Martins, D. A.; Weinhäuser, I.; Almeida, L. Y.; Bianco, T. M.; Figueiredo-Pontes, L. L.; Koury, L. C. A.; Melo, R. A. M.; Bittencourt, R.; Pagnano, K. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II clinical trial of CPI-613 (devimistat) in patients with relapsed or refractory burkitt lymphoma/leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2and/or BCL6
    Meeting Abstract

    Noy, A.; Pardee, T. S.; Nikolaenko, L.; Steiner, R. E.; Abramson, J. S.; Dunleavy, K.; Luther, S.
    Blood (2019)

    Fulltext@MSK | Save
  • Dynamic easix scores closely predict non-relapse mortality after allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Nawas, M. T.; Sanchez-Escamilla, M.; Devlin, S. M.; Maloy, M. A.; Giralt, S. A.; Perales, M. A.; Scordo, M.
    Blood (2019)

    Fulltext@MSK | Save
  • Preliminary results from a phase II study of the combination of pevonedistat and azacitidine in the treatment of MDS and MDS/MPN after failure of DNA methyltransferase inhibition
    Meeting Abstract

    Moyo, T. K.; Watts, J. M.; Skikne, B. S.; Mendler, J. H.; Klimek, V. M.; Chen, S. C.; Fan, R.; Anderson, I. A.; Sochacki, A.; Strickland, S. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Igcaller: Reconstructing the rearranged immunoglobulin gene in lymphoid neoplasms from whole-genome sequencing data
    Meeting Abstract

    Nadeu, F.; Mas-de-les-Valls, R.; Royo, R.; Navarro, A.; Beà, S.; Lu, J.; Rivas-Delgado, A.; Villamor, N.; Martín, S.; Aymerich, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Molecular characteristics that predict response to azacitidine therapy
    Meeting Abstract

    Nannya, Y.; Tobiasson, M.; Bernard, E.; Sato, S.; Creignou, M.; Takeda, J.; Zhao, L.; Shiraishi, Y.; Chiba, K.; Tanaka, H.; more...
    Blood (2019)

    Fulltext@MSK | Save